Abstract:To investigate the relationship between the expression of phosphoenolpyruvate carboxykinase (PEPCK) gene and insulin resistance induced by high-fat diet and the effect of rosiglitazone, a thiazolidinedione drug.Sixty-three normal 8-week-old male SD rats were randomly divided into 2 groups: short-term group, n = 33, to be fed for 8 weeks and re-divide into 3 equal subgroups: standard chow diet subgroup (NC subgroup fed with standard chow diet), high-fat diet subgroup (HF subgroup, to be fed with lard), and high-fat diet with rosiglitazone subgroup (HF + rosiglitazone subgroup); and long-term group, n = 30, to be fed for 28 weeks, and re-divided into 3 corresponding 3 subgroups: By the end of experiment, serum samples were collected to examine the blood glucose (BG), triglyceride (TG) and free fatty acid (FFA). At the end of the experiment the rats were killed and the visceral adipose tissue was taken out to be weighed, and the liver, muscle, and epididymis were isolated. Glucose infusion rate (GIR) methods and tissue uptake of (3)H-2-deoxyglucose were used to short-and long-term groups evaluate the insulin sensitivity. PEPCK gene expression was investigated to detect the expression of PEPCK mRNA by using semi-quantitative RT-PCR method.In the short-term group, the serum FFA and TG of the HF + rosiglitazone subgroup were lower by 24.5% and 54.0% respectively compared with those the HF subgroup (both P < 0.01). In the long-term group, the serum TG of the HF subgroup was higher by 32.4% in comparison with that of the NC subgroup (P < 0.05), and the serum FFA and TG of the HF + rosiglitazone subgroup were lower by 49.5% and 23.0% respectively compared with those of the HF subgroup (both P < 0.0). In the short-term group the GIR of the HF subgroup was lower by 51.25% in comparison with that of the NC subgroup (P < 0.01). And the GIR of the HF + rosiglitazone subgroup was higher by 149.6% than that of the HF group (P < 0.01). In the long-term group, the rate of uptake of (3)H-2-deoxyglucose in liver, muscle and adipose tissue of the HF subgroup were lower by 42.0%, 36.7%, and 48.1% respectively than those of the HF subgroup (all P < 0.01), and the rate of uptake of 3H-2-deoxyglucose in liver, muscle and adipose tissue of the HF + rosiglitazone subgroup were higher by 39.6%, 66.3%, and 66.7% respectively than those of the HF subgroup (all P < 0.01). In the short-term group the adipose PEPCK mRNA expression of the HF subgroup was 89% +/- 13% that of the NC subgroup; and the adipose PEPCK mRNA expression of the HF + rosiglitazone subgroup was 154% +/- 28% that of the NC subgroup, and was higher by 65.4% than that the HF subgroup (P < 0.05). In the long-term group, the adipose PEPCK mRNA expression of the HF + rosiglitazone subgroup was 144% +/- 17% that of the NC subgroup (P < 0.05), and was higher by 43.3% than that of the HF subgroup (P < 0.05).Thiazolidinedione drug increases the re-esterification of fatty acids and reduces circulating FFA, and induces the expression of adipose PEPCK which is accompanied by reduction of FFA, thus improving insulin resistance.

The effect of rosiglitazone on non-alcoholic fatty liver in experimental rats

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Research on the Protection Effect of Pioglitazone for Non-Alcoholic Fatty Liver Disease (NAFLD) in Rats

Effect of rosiglitazone on the expressions of interleukin-18 and caspase-1 in the liver tissue of animal models of non-alcoholic fatty liver disease

Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats]

Effects of high fat diet and rosiglitazone treatment on insulin signal system gene expression

[Preventive Effects of Pioglitazone on Rat Fatty Liver Induced by a High Fat Diet].

[The Effect of High Fat Feeding and Rosiglitazone Intervention on Pancreatic Alpha Cell in Rats].

Inhibition of Hepatic Interleukin-18 Production by Rosiglitazone in A Rat Model of Nonalcoholic Fatty Liver Disease

The effect of rosiglitazone on the serum intercellular adhesion molecule-1 ( ICAM-1 ) levels of diabetic rats

Pathological changes of aorta,liver in type 2 diabetes rat and the intervention study of rosiglitazone

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

Rosiglitazone alleviates vascular endothelial dysfunction in type 2 diabetic rats

Effects of “xiaogao Zhuanzhuo Decoction” on Lipid Peroxidation and Insulin Resistance in Rats of Obese Non-alcoholic Fatty Liver

Experimental study on the protective effects of rosiglitazone on aortic endothelial cells of spontaneously type 2 diabetic rats

The effect of rosiglitazone on the urinary protein excretion of diabetic rats

Effect of Rosiglitazone on the Function and Morphology of Pancreatic Beta-Cell in Type 2 Diabetic Rats

Protein Expression of LOX-1, Enos and PPARγin Liver of Rats with Type 2 Diabetes and Intervention of Rosiglitazone

The effects of Rosiglitazone on the levels of cytokine in patients with IGT and metabolic syndrome

Efficacy and safety of rosiglitazone hydrochloride in the treatment of patients with type 2 diabetes mellitus

Relationship between adipose phosphoenolpyruvate carboxykinase and occurrence and reversion of insulin resistance]